A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OXFORD NANOPORE TECHNOLOGIES PL operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 234M | 234M | 212M | 245M | 184M |
| Net Income | -187M | -187M | -193M | - | - |
| EPS | $0.00 | - | - | $0.14 | $0.32 |
| Free Cash Flow | -158M | -158M | -179M | -89M | -103M |
| ROIC | -31.1% | -25.8% | -30.2% | -24.4% | -53.5% |
| Gross Margin | 57.5% | 57.5% | 53.3% | 62.3% | 54.8% |
| Debt/Equity | 0.00 | 0.08 | 0.07 | 0.06 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -195M | -195M | -210M | -121M | -226M |
| Operating Margin | -83.2% | -83.2% | -99.4% | -49.6% | -123.1% |
| ROE | -24.9% | -24.1% | -23.3% | - | - |
| Shares Outstanding | 0M | - | - | - | - |
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 184M | 245M | 212M | 234M | 234M |
| Gross Margin | 54.8% | 62.3% | 53.3% | 57.5% | 57.5% |
| R&D | -104M | -85M | -130M | -127M | -127M |
| SG&A | -222M | -194M | N/A | N/A | N/A |
| EBIT | -226M | -121M | -210M | -195M | -195M |
| Op. Margin | -123.1% | -49.6% | -99.4% | -83.2% | -83.2% |
| Net Income | N/A | N/A | -193M | -187M | -187M |
| Net Margin | N/A | N/A | -91.1% | -79.8% | -79.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -53.5% | -24.4% | -30.2% | -25.8% | -31.1% |
| ROE | N/A | N/A | -23.3% | -24.1% | -24.9% |
| ROA | N/A | N/A | -19.4% | -19.5% | -19.7% |
| Cash Flow | |||||
| Op. Cash Flow | -73M | -79M | -171M | -141M | -141M |
| Free Cash Flow | -103M | -89M | -179M | -158M | -158M |
| Owner Earnings | -73M | -79M | -171M | -141M | -141M |
| CapEx | 30M | 11M | 7.4M | 18M | 18M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | 18M |
| D&A | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 12M | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | -625M | -392M | -220M | -199M | -255M |
| Cash & Equiv. | 671M | 440M | 275M | 255M | 255M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.05 | 0.06 | 0.07 | 0.08 | 0.00 |
| Interest Coverage | -181.2 | -60.5 | -76.4 | -42.7 | -42.7 |
| Equity | 968M | 855M | 804M | 750M | 750M |
| Total Assets | 1.2B | 1.0B | 970M | 949M | 949M |
| Total Liabilities | 190M | 161M | 166M | 199M | 199M |
| Intangibles | N/A | N/A | 41M | 56M | 56M |
| Retained Earnings | -22M | -131M | -322M | -514M | -514M |
| Working Capital | 887M | 674M | 447M | 523M | 523M |
| Current Assets | 1.0B | 786M | 558M | 665M | 665M |
| Current Liabilities | 144M | 113M | 111M | 143M | 143M |
| Per Share Data | |||||
| EPS | 0.32 | 0.14 | N/A | N/A | 0.00 |
| Owner EPS | N/A | N/A | N/A | N/A | N/A |
| Book Value | N/A | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | N/A | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | N/A | N/A | N/A | 0.0M |
| Valuation | |||||
| P/E Ratio | 30.3 | 22.0 | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 |
| Avg. Price | 8.51 | 4.29 | 2.82 | 1.68 | 1.13 |
| Year-End Price | 9.58 | 2.99 | 2.56 | 1.80 | 1.13 |
OXFORD NANOPORE TECHNOLOGIES PL passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 57.0%.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) has a 5-year average return on invested capital (ROIC) of -33.5%. This is below average and may indicate limited pricing power.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) does not currently pay a regular dividend.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) operates in the Biotechnology industry, within the Healthcare sector.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) reported annual revenue of $234 million in its most recent fiscal year, based on SEC EDGAR filings.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) has a net profit margin of -79.8%. The company is currently unprofitable.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) generated $-158 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) has a return on equity (ROE) of -24.1%. A negative ROE may indicate losses or negative equity.
OXFORD NANOPORE TECHNOLOGIES PL (ONT-L) has a 5-year average gross margin of 57.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for OXFORD NANOPORE TECHNOLOGIES PL (ONT-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.